CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,585,411
- in 7 filings, $4.5M under 10b5-1 plans
Net −$6,585,411. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-04 | Reardon Andrew CLO & Secretary | Grant or award | +6,415 | 34,783 | ||
| 2025-03-04 | Reardon Andrew CLO & Secretary | Grant or award · Employee Stock Option (right to buy) | +28,043 | 28,043 | ||
| 2025-03-04 | Espinoza Octavio Chief Financial Officer | Sale | −5,000 | $115.03 | $575K | 18,879 |
| 2025-03-04 | Espinoza Octavio Chief Financial Officer | Grant or award | +7,484 | 26,363 | ||
| 2025-03-04 | Espinoza Octavio Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +32,717 | 32,717 | ||
| 2025-03-04 | Davis Todd C Chief Executive Officer | Grant or award | +21,382 | 151,724 | ||
| 2025-03-04 | Davis Todd C Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +93,476 | 93,476 | ||
| 2025-02-15 | Davis Todd C Chief Executive Officer | Shares withheld for taxes | −2,231 | $120.00 | $268K | 134,597 |
| 2025-02-15 | Davis Todd C Chief Executive Officer | Shares withheld for taxes | −4,255 | $120.00 | $511K | 130,342 |
| 2025-02-15 | Espinoza Octavio Chief Financial Officer | Shares withheld for taxes | −1,024 | $120.00 | $123K | 25,882 |
| 2025-02-15 | Espinoza Octavio Chief Financial Officer | Shares withheld for taxes | −782 | $120.00 | $94K | 25,100 |
| 2025-02-15 | Espinoza Octavio Chief Financial Officer | Shares withheld for taxes | −1,221 | $120.00 | $147K | 23,879 |
| 2025-02-15 | Reardon Andrew CLO & Secretary | Shares withheld for taxes | −1,114 | $120.00 | $134K | 29,244 |
| 2025-02-15 | Reardon Andrew CLO & Secretary | Shares withheld for taxes | −876 | $120.00 | $105K | 28,368 |
| 2025-02-14 | Davis Todd C Chief Executive Officer | Grant or award | +20,784 | 143,794 | ||
| 2025-02-14 | Davis Todd C Chief Executive Officer | Shares withheld for taxes | −6,966 | $120.00 | $836K | 136,828 |
| 2025-02-14 | Espinoza Octavio Chief Financial Officer | Grant or award | +5,429 | 26,076 | ||
| 2025-02-14 | Espinoza Octavio Chief Financial Officer | Shares withheld for taxes | −2,757 | $120.00 | $331K | 23,319 |
| 2025-02-14 | Espinoza Octavio Chief Financial Officer | Grant or award | +7,390 | 30,709 | ||
| 2025-02-14 | Espinoza Octavio Chief Financial Officer | Shares withheld for taxes | −3,803 | $120.00 | $456K | 26,906 |
Page 17 of 43 · 858 trades